Navigating the CMS 14-Day Rule in Biomarker Testing

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

Related Videos

January 20, 2016

Do Therapeutic Agents Affect Healthy Stem Cells?

Dr Wainberg and Dr Gerson ponder and provide opinions on whether these investigational therapies also target healthy cells.

March 31, 2015

Reality of the ASPIRE Study

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate [ Read More ]